Eikon Therapeutics filed with the SEC indicating it is considering a Nasdaq IPO to accelerate development of a multi‑program oncology pipeline. The California biotech—backed by more than $1.1 billion in private financing—said proceeds would primarily support advancement of four clinical‑stage candidates, including EIK1001 (TLR7/8 co‑agonist) in Phase III for advanced melanoma and EIK1003, a PARP1 inhibitor in Phase I across multiple cancers. Eikon also disclosed planning to start a Phase I for EIK1004, a CNS‑penetrant PARP1‑selective inhibitor aimed at brain cancers, and listed several earlier‑stage assets including androgen receptor antagonists and a Werner syndrome protein inhibitor. The filing did not disclose offering size or pricing. The move follows Aktis Oncology’s 2026 IPO and was framed by analysts as a potential sign of renewed public‑market receptivity for oncology biotechs should clinical readouts and financing markets remain constructive.